Daughter – Medicine [subtitulado espaol] + Lyrics (Official Video) – Video

Posted on by


Daughter - Medicine [subtitulado espaol] + Lyrics (Official Video)
Daughter - Medicine Cinematics #39; #39;The Division Of Gravity #39; #39; By #39; #39;Rob Chiu #39; #39; http://icanseeyoustayinghere.tumblr.com/ http://instagram.com/belml24 https://twitter.com/MendozaBell24 https://www.face...

By: Bel Mendoza

Read the rest here:

Daughter - Medicine [subtitulado espaol] + Lyrics (Official Video) - Video

Regenerative medicine approach improves muscle strength, function in leg injuries

Posted on by

PUBLIC RELEASE DATE:

30-Apr-2014

Contact: Anita Srikameswaran SrikamAV@upmc.edu 412-578-9193 University of Pittsburgh Schools of the Health Sciences

PITTSBURGH, April 30, 2014 Damaged leg muscles grew stronger and showed signs of regeneration in three out of five men whose old injuries were surgically implanted with extracellular matrix (ECM) derived from pig bladder, according to a new study conducted by researchers at the University of Pittsburgh School of Medicine and the McGowan Institute for Regenerative Medicine. Early findings from a human trial of the process and from animal studies were published today in Science Translational Medicine.

When a large volume of muscle is lost, typically due to trauma, the body cannot sufficiently respond to replace it, explained senior investigator Stephen F. Badylak, D.V.M., Ph.D., M.D., professor of surgery at Pitt and deputy director of the McGowan Institute, a joint effort of Pitt and UPMC. Instead, scar tissue can form that significantly impairs strength and function.

Pig bladder ECM has been used for many years as the basis for medical products for hernia repair and treatment of skin ulcers. It is the biologic scaffold that remains left behind after cells have been removed. Previous research conducted by Dr. Badylak's team suggested that ECM also could be used to regenerate lost muscle by placing the material in the injury site where it signals the body to recruit stem and other progenitor cells to rebuild healthy tissue.

"This new study is the first to show replacement of new functional muscle tissue in humans, and we're very excited by its potential," Dr. Badylak said. "These are patients who can't walk anymore, can't get out of a car, can't get up and down from a chair, can't take steps without falling. Now we might have a way of helping them get better."

For the Muscle Tendon Tissue Unit Repair and Reinforcement Reconstructive Surgery Research Study, which is sponsored by the U.S. Department of Defense and is continuing to enroll new participants, five men who had at least six months earlier lost at least 25 percent of leg muscle volume and function compared to the uninjured limb underwent a customized regimen of physical therapy for 12 to 26 weeks until their function and strength plateaued for a minimum of two weeks.

Then, study lead surgeon J. Peter Rubin, M.D., UPMC Professor and chair of plastic surgery, Pitt School of Medicine, surgically implanted a "quilt" of compressed ECM sheets designed to fill into their injury sites. Within 48 hours of the operation, the participants resumed physical therapy for up to 26 additional weeks.

The researchers found that three of the participants, two of whom had thigh injuries and one a calf injury, were stronger by 20 percent or more six months after the surgery. One thigh-injured patient improved on the "single hop test" by 1,820 percent, and the other had a 352 percent improvement in a chair lift test and a 417 percent improvement in the single-leg squat test. Biopsies and scans all indicated that muscle growth had occurred. Two other participants with calf injuries did not have such dramatic results, but both improved on at least one functional measure and said they felt better.

Read more:

Regenerative medicine approach improves muscle strength, function in leg injuries

New experimental vaccine produces immune response against MERS virus

Posted on by

PUBLIC RELEASE DATE:

30-Apr-2014

Contact: Christopher Hardwick chardwick@som.umaryland.edu 410-706-5260 University of Maryland School of Medicine

The University of Maryland School of Medicine (UM SOM) and Novavax, Inc. (NASDAQ: NVAX) today announced that an investigational vaccine candidate developed by Novavax against the recently emerged Middle East Respiratory Syndrome Coronavirus (MERS-CoV) blocked infection in laboratory studies. UM SOM and Novavax also reported that a vaccine candidate against Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) developed by Novavax on a similar platform also inhibited virus infection. Researchers reported these findings in an article published in the April 13, 2014 issue of Vaccine1.

Historically, vaccine strategies for emerging pathogens have been limited due to the sudden nature in which the virus first appears and delayed by the protracted traditional vaccine development process. This peer-reviewed manuscript describes a novel method to rapidly develop vaccines against previously unknown viruses, such as MERS-CoV, which appear suddenly and cause severe illnesses in humans. The experimental vaccines, which were tested in conjunction with Novavax' proprietary adjuvant Matrix-M, induced neutralizing antibodies, or immune responses, that prevent viruses from infecting cells.

"Our protein nanoparticle vaccine technology is proving to have the potential to respond rapidly to emerging viruses such as MERS-CoV and certain potential pandemic influenza strains, addressing what are clearly urgent public health needs," said Gale Smith, Ph.D., Vice President of Vaccine Development at Novavax. "Novavax will continue to evaluate this technology to produce highly immunogenic nanoparticles for coronavirus, influenza, and other human disease pathogens with the potential for pandemic and sustained human to human transmission."

"The emergence of SARS-CoV and MERS-CoV demonstrates how coronaviruses can spillover from animals into humans at any time, causing lethal disease," said Matthew B. Frieman, Ph.D., Assistant Professor of Microbiology and Immunology at the University of Maryland School of Medicine and corresponding author on the publication. "Despite efforts to create a vaccine against SARS-CoV, no vaccine candidate has, to date, been successfully licensed for use. We have demonstrated that this novel method rapidly creates SARS-CoV and MERS-CoV vaccines that induce neutralizing antibodies in mice."

"The University of Maryland School of Medicine investigators are continually working toward a better understanding of the interactions between the human immune system and a variety of known and novel harmful microbes," said E. Albert Reece, Vice President of Medical Affairs, the University of Maryland and the John Z. and Akiko Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. "This makes our faculty poised to respond to emerging infectious diseases, such as MERS-CoV, which threaten the health and wellbeing of the global population."

The vaccine candidates were made using Novavax' recombinant nanoparticle vaccine technology and based on the major surface spike (S) protein, a SARS-CoV and MERS-CoV surface protein responsible for attaching the virus to cells. Novavax previously demonstrated that spike protein nanoparticles could protect animals against lethal live challenge using the SARS-CoV virus2.

###

Continued here:

New experimental vaccine produces immune response against MERS virus

Traditional and Complementary Medicine Act will ensure quality service Dr Subramaniam

Posted on by

PUTRAJAYA: The Traditional and Complementary Medicine Act 2013 which is expected to be fully enforced by the end of the year is in the best interests of patients and will also ensure quality service, said Health Minister Datuk Seri Dr S Subramaniam.

Describing the Act as a move to create a recognised and systematic service, Dr Subramaniam said it was critical as right now the Ministry had no authority over alternative medicine practitioners.

However, with this Act we can ensure that only qualified, recognised and accredited practitioners are allowed to offer such services, he said after chairing a meeting here yesterday.

Gazetted in February 2013, the Act would also make it mandatory for all traditional and complementary medicine practitioners to register themselves with the Traditional and Complementary Medicine Council, he added.

Subramaniam said the ministry had appointed eight bodies to represent and self-regulate their identified fields of practice based on a code of ethics and practice developed by the ministry and constitutions of the bodies concerned.

The six main fields of practice were Malay traditional medicine, Indian traditional medicine, Chinese traditional medicine, Islamic medicine, homeopathy and complementary therapy, he noted. Bernama

Read more:

Traditional and Complementary Medicine Act will ensure quality service Dr Subramaniam

How Do You Help Your EGFR Patients Make Treatment Decisions When Their Cancers Grow? – Video

Posted on by


How Do You Help Your EGFR Patients Make Treatment Decisions When Their Cancers Grow?
Dr. Geoffrey Oxnard from Harvard Medical School talks about EGFR treatment decisions, filmed at IASLC in February 2014. Oncology.TV would like to acknowledge CancerGrace.org and the Lungevity...

By: Oncology.TV

Link:

How Do You Help Your EGFR Patients Make Treatment Decisions When Their Cancers Grow? - Video

Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive NSCLC? – Video

Posted on by


Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive NSCLC?
Dr. Joel Neal from Stanford University Medical School talks about erlotinib, filmed at IASLC in February 2014. Oncology.TV would like to acknowledge CancerGrace.org and the Lungevity Foundation...

By: Oncology.TV

Read more:

Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive NSCLC? - Video

What’s the Status and Potential Utility of Cabozantinib in Lung Cancer? – Video

Posted on by


What #39;s the Status and Potential Utility of Cabozantinib in Lung Cancer?
Dr. Heather Wakelee from Stanford University Medical School talks about the status and potential utility of cabozantinib in lung cancer, filmed at IASLC in February 2014. Oncology.TV would...

By: Oncology.TV

Go here to read the rest:

What's the Status and Potential Utility of Cabozantinib in Lung Cancer? - Video

Molecular Testing for Early Stage Lung Cancer Patients – Is it Necessary? – Video

Posted on by


Molecular Testing for Early Stage Lung Cancer Patients - Is it Necessary?
Dr. Joel Neal from Stanford University Medical School talks about molecular testing, filmed at IASLC in February 2014. Oncology.TV would like to acknowledge CancerGrace.org and the Lungevity...

By: Oncology.TV

See original here:

Molecular Testing for Early Stage Lung Cancer Patients - Is it Necessary? - Video

BIDMC's Martin Pollak, M.D., elected to National Academy of Sciences

Posted on by

PUBLIC RELEASE DATE:

30-Apr-2014

Contact: Bonnie Prescott bprescot@bidmc.harvard.edu 617-667-7306 Beth Israel Deaconess Medical Center

BOSTON Martin R. Pollak, MD, Chief of Nephrology at Beth Israel Deaconess Medical Center (BIDMC) and Professor of Medicine at Harvard Medical School, is among 84 new members and 21 foreign associates elected to the National Academy of Sciences (NAS). NAS fellows are chosen for distinguished and continuing achievements in original research.

The NAS is a private, nonprofit institution that was established under a congressional charter signed by President Lincoln in 1863. The academy recognizes achievement in science through election to its membership, and it also provides science, engineering and health policy advice to the federal government and other organizations. Scientists are elected by their peers to membership, and as the role of science has expanded in the United States, the National Academy has grown to include the Institute of Medicine, the National Academy of Engineering and the National Research Council.

Pollak joins BIDMC's Richard Sidman, MD, as an NAS member. BIDMC faculty members Jeffrey S. Flier, MD, Jerome E. Groopman, MD, Barbara B. Kahn, MD, Clifford B. Saper, MD, PhD, and Sharon K. Inouye, MD, MPH, are elected members of the Institute of Medicine.

Pollak's research has identified the genes involved in the development of focal segmental glomerulosclerosis (FSGS), a common form of renal injury which disproportionately strikes African Americans. His work has shown that two common coding sequence variants in the APOL1 gene confer both resistance to trypanosome b. rhodiesiense infection (an African sleeping sickness agent) and a seven-to-ten-fold increased susceptibility to FSGS and hypertension-associated kidney disease.

"Of the half a million people in the U.S. with kidney disease, one in three are African American," says Mark Zeidel, MD, PhD, Chairman of Medicine at BIDMC. "Martin Pollak's discovery that the APOL1 gene confers this risk helps us in our efforts to address and, hopefully, eliminate this disease disparity."

"Martin Pollak's investigations into the genetics and biology of this widespread disease hold great promise for the field of nephrology," adds BIDMC Chief Academic Officer Vikas P. Sukhatme, MD, PhD. "The next key step will be to identify the mechanisms by which mutations in the APOL1 gene lead to a greater propensity for kidney damage. This innovative research is a tremendous example of how laboratory discoveries reach our patients, and could help clinicians to better tailor treatments to specific forms of kidney disease. Dr. Pollak's election to the NAS is a reflection of this critically important work."

###

See more here:

BIDMC's Martin Pollak, M.D., elected to National Academy of Sciences

68 Stuyvesant Ave Jersey City NJ 07306 – Megha Moza – Liberty Realty – Obeo Virtual Tour 880270 – Video

Posted on by


68 Stuyvesant Ave Jersey City NJ 07306 - Megha Moza - Liberty Realty - Obeo Virtual Tour 880270
http://homesite.obeo.com/viewer/default.aspx?tourid=880270 refURL=youtube Contact: Megha Moza Liberty Realty 201.659.2555 mmoza@libertyrealestate.com for more information about this home.

By: Liberty Realty Property Tours

Originally posted here:

68 Stuyvesant Ave Jersey City NJ 07306 - Megha Moza - Liberty Realty - Obeo Virtual Tour 880270 - Video